Cytiva invests $1.6B in global manufacturing capacity with an ‘in-region, for-region’ focus

With an investment of $1.6 billion since 2019, Cytiva announced Wednesday that several capital expenditure projects have been completed — while others are on track — to expand the life sciences company’s capacity and enhance its global supply chain through an “in-region, for-region” manufacturing strategy. 

Part of Danaher Corporation, Cytiva offers a range of products and services for both biotechnology development and manufacturing. Wednesday’s update on its infrastructure investment, which is slated to continue through 2028, is in alignment with Cytiva’s long-term growth plan to meet increased customer demand. 

“Customers now benefit from faster delivery across Cytiva’s portfolio, including chromatography resins, filtration, single-use bags and cell culture media,” according to the announcement.

Cytiva has effectively doubled production capacity of chromatography resins manufacturing in Uppsala, Sweden, with the addition of new factories, equipment, improved automation capabilities, as well as a new tank farm for solvent storage. In the U.S., the company is building a second resins manufacturing site in Muskegon, Michigan, which is expected to be fully operational by end of 2028.

When it comes to filtration, Cytiva’s investment in new manufacturing lines in Pensacola, Florida, will increase the site’s production capacity for filter membranes for North America by 20% by August 2025. In 2026, the company’s Innovation Hub and facility in South Korea will start filtration manufacturing to address increased demand in Asia-Pacific.  

Cytiva also announced that upgrades and expansions in filtration manufacturing in Fajardo, Puerto Rico are boosting capacity by 33%, while expanded filtration device manufacturing in Ilfracombe, U.K. is improving capacity by 81%.

Single-use bags, which enable customers to quickly and efficiently work with and change batches during their processes, are part of Cytiva’s latest capacity investments. The projects include the trebling of single-use consumable manufacturing capacity in Beijing, China, doubling of manufacturing capacity in Duncan, South Carolina, and sustained manufacturing capacity in Medemblik, Netherlands.

In the U.S., Cytiva is increasing access to cell culture media by expanding dry powder and liquid media manufacturing capacity in Logan, Utah, for large volumes and adding high-speed bottle filling for small volumes. An expanded staging area for finished goods and a new centralized 10,000-square-foot quality control laboratory are currently supporting increased manufacturing, with 73,850 square feet of expansions planned through 2026.

Cytiva and synthetic biology company Asimov announced in April they partnered to offer biomanufacturers a full suite of cell line development and cell culture services designed to accelerate the production of protein biologics, including complex formats. The teaming combines Cytiva’s HyClone media and Fast Trak process development services and Asimov’s CHO Edge platform in a unified workflow.

Tariff headwinds, regionalization

Danaher expects $350 million in incremental tariff-related costs in 2025 but says it can largely offset the impact through surcharges, supply chain management, cost actions, and relocating manufacturing.

“The macro backdrop has become more dynamic since the start of the year, with rising geopolitical and trade tensions contributing to greater uncertainty across global markets,” Danaher CEO Rainer Blair told analysts in an April 22 earnings call.

However, Blair pointed to Cytiva’s regionalization of its U.S. bioprocessing capacity over the last five years, which he contends will help ensure supply chain security for the company and its customers.

“These additions include new single-use technology facilities in South Carolina, filter capacity expansions in Florida, and a cell culture media expansion in Utah, all of which are now online, as well as the resins manufacturing plant in Michigan that is nearing completion,” Blair said.

Large pharmaceutical companies and contract development and manufacturing organizations (CDMOs) have similarly put in place strategies for regional redundancy and capacity distribution to deal with the threat of tariffs and enhance global supply chains.

“Near term, this capacity is critical for supporting existing customer demand, but it’s equally important to support Cytiva’s robust long-term growth outlook and illustrates our in-region, for-region manufacturing strategy,” Blair said, noting that the company has been regionalizing its manufacturing network of over 100 plants for several years “so we have a combination of both short-term and long-term countermeasures.”